Quantitative Analysis of Background Intraocular Pressure Volatility and Retinal Nerve Fiber Layer Loss in Cytomegalovirus Anterior Uveitis

巨细胞病毒性前葡萄膜炎中背景眼压波动和视网膜神经纤维层丢失的定量分析

阅读:1

Abstract

PURPOSE: To evaluate intraocular pressure (IOP) volatility and long-term glaucomatous progression in cytomegalovirus anterior uveitis (CMV AU). METHODS: We analyzed 63 eyes with polymerase chain reaction-confirmed CMV AU (53 patients) with ≥18 months follow-up, ≥10 IOP measurements, and ≥4 optical coherence tomography (OCT) scans. A total of 2304 IOP and 451 OCT measurements were obtained over 5.4 ± 3.1 years. Background IOP volatility was defined as standard deviation (SDb) and coefficient of variation (CVb), excluding IOP >24 mm Hg. Retinal nerve fiber layer (RNFL) thinning was assessed by linear regression. Initial treatment response (ITR) was defined as IOP normalization and inflammation reduction within two weeks. RESULTS: Posner-Schlossman syndrome accounted for 95.2% of cases. Mean IOP was 16.4 ± 7.8 mm Hg in lesion eyes and 14.6 ± 3.0 mm Hg in fellow eyes. Background IOP volatility was 1.7-fold higher in lesion eyes (SDb ratio 1.70 ± 0.74, CVb ratio 1.74 ± 0.69; P < 0.001). Overall, 60.4% showed RNFL thinning. Median RNFL loss rate in lesion eyes was 1.40 µm/year versus 0.81 µm/year in fellow eyes. Univariable predictors included number of attacks (P = 0.012), ITR failure (P = 0.001), and SDb (P = 0.045); ITR failure remained significant in multivariable analysis. Receiver operating characteristic analysis suggested SDb >2.5 mm Hg and CVb >0.17 as possible cutoffs for CMV involvement. CONCLUSIONS: CMV AU eyes showed 1.7 × higher background IOP volatility than fellow eyes during normotensive intervals, with RNFL loss in 60% (median 1.40 µm/year). These findings highlight the chronic and aggressive nature of CMV AU. IOP volatility may serve as a supportive biomarker. TRANSLATIONAL RELEVANCE: Quantifying background IOP volatility provides a clinically accessible surrogate linking CMV-related trabecular pathology to glaucomatous progression.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。